Inhibition of neprilysin with sacubitril without RAS blockage aggravates renal disease in Dahl SS rats

References

• Benjamin EJ, Muntner P, Alonso A, et al. Heart Disease and Stroke Statistics-2019 update: a report from the american heart association. Circulation. 2019;139(10):e56–e528.
   PubMed Web of Science ®Google Scholar
• Elijovich F, Weinberger MH, Anderson CA, et al. Salt sensitivity of blood pressure: a scientific statement from the American Heart Association. Hypertension. 2016;68(3):e7–e46.
   PubMedGoogle Scholar
• Liu K, Xi B, Liu Z, et al. Genetic predisposition and salt sensitivity in a Chinese Han population: the EpiSS study. Int J Hypertens. 2020;2020:3167875.
   PubMed Web of Science ®Google Scholar
• Weinberger MH. Salt sensitivity of blood pressure in humans. Hypertension. 1996;27(3 Pt 2):481–490.
   PubMed Web of Science ®Google Scholar
• Svetkey LP, McKeown SP, Wilson AF. Heritability of salt sensitivity in black Americans. Hypertension. 1996;28(5):854–858.
   PubMed Web of Science ®Google Scholar
• Dahl LK, Heine M, Tassinari L. Effects of chronic excess salt ingestion. Role of genetic factors in both doca-salt and renal hypertension. J Exp Med. 1963;118:605–617.
   PubMed Web of Science ®Google Scholar
• Bijleveld CM, Vonk RJ, Kuipers F, et al. Benign recurrent intrahepatic cholestasis: altered bile acid metabolism. Gastroenterology. 1989;97(2):427–432.
   PubMed Web of Science ®Google Scholar
• Lackland DT, Egan BM. Dietary salt restriction and blood pressure in clinical trials. Curr Hypertens Rep. 2007;9(4):314–319.
   PubMed Web of Science ®Google Scholar
• Majid DS, Prieto MC, Navar LG. Salt-sensitive hypertension: perspectives on intrarenal mechanisms. Curr Hypertens Rev. 2015;11(1):38–48.
   PubMed Web of Science ®Google Scholar
• Dahl LK, Schackow E. Effects of chronic excess salt ingestion: experimental hypertension in the rat. Can Med Assoc J. 1964;90:155–160.
   PubMed Web of Science ®Google Scholar
• Bigazzi R, Bianchi S, Baldari D, et al. Microalbuminuria in salt-sensitive patients. A marker for renal and cardiovascular risk factors. Hypertension. 1994;23(2):195–199.
   PubMed Web of Science ®Google Scholar
• Bihorac A, Tezcan H, Ozener C, et al. Association between salt sensitivity and target organ damage in essential hypertension. Am J Hypertens. 2000;13(8):864–872.
   PubMed Web of Science ®Google Scholar
• Campese VM. Salt sensitivity in hypertension. Renal and cardiovascular implications. Hypertension. 1994;23(4):531–550.
   PubMed Web of Science ®Google Scholar
• Drenjancevic-Peric I, Jelakovic B, Lombard JH, et al. High-salt diet and hypertension: focus on the renin-angiotensin system. Kidney Blood Press Res. 2011;34(1):1–11.
   PubMed Web of Science ®Google Scholar
• Rapp JP. Dahl salt-susceptible and salt-resistant rats. A review. Hypertension. 1982;4(6):753–763.
   PubMed Web of Science ®Google Scholar
• de la Sierra A, Lluch MM, Coca A, et al. Fluid, ionic and hormonal changes induced by high salt intake in salt-sensitive and salt-resistant hypertensive patients. Clin Sci. 1996;91(2):155–161.
   Web of Science ®Google Scholar
• Poch E, Gonzalez D, Giner V, et al. Molecular basis of salt sensitivity in human hypertension. Evaluation of renin-angiotensin-aldosterone system gene polymorphisms. Hypertension. 2001;38(5):1204–1209.
   PubMed Web of Science ®Google Scholar
• Tank JE, Moe OW, Henrich WL. Abnormal regulation of proximal tubule renin mRNA in the Dahl/Rapp salt-sensitive rat. Kidney Int. 1998;54(5):1608–1616.
   PubMed Web of Science ®Google Scholar
• Campbell WG, Jr., Gahnem F, Catanzaro DF, et al. Plasma and renal prorenin/renin, renin mRNA, and blood pressure in Dahl salt-sensitive and salt-resistant rats. Hypertension. 1996;27(5):1121–1133.
   PubMed Web of Science ®Google Scholar
• Iwai J, Dahl LK, Knudsen KD. Genetic influence on the renin-angiotensin system: low renin activities in hypertension-prone rats. Circ Res. 1973;32(6):678–684.
   PubMed Web of Science ®Google Scholar
• Kobori H, Nishiyama A, Abe Y, et al. Enhancement of intrarenal angiotensinogen in Dahl salt-sensitive rats on high salt diet. Hypertension. 2003;41(3):592–597.
   PubMed Web of Science ®Google Scholar
• Kaplinsky E. Sacubitril/valsartan in heart failure: latest evidence and place in therapy. Ther Adv Chronic Dis. 2016;7(6):278–290.
   PubMed Web of Science ®Google Scholar
• Wong PC, Guo J, Zhang A. The renal and cardiovascular effects of natriuretic peptides. Adv Physiol Educ. 2017;41(2):179–185.
   PubMed Web of Science ®Google Scholar
• Ogawa Y, Mukoyama M, Yokoi H, et al. Natriuretic peptide receptor guanylyl cyclase-A protects podocytes from aldosterone-induced glomerular injury. J Am Soc Nephrol. 2012;23(7):1198–1209.
   PubMed Web of Science ®Google Scholar
• Das S, Au E, Krazit ST, et al. Targeted disruption of guanylyl cyclase-A/natriuretic peptide receptor-A gene provokes renal fibrosis and remodeling in null mutant mice: role of proinflammatory cytokines. Endocrinology. 2010;151(12):5841–5850.
   PubMed Web of Science ®Google Scholar
• Salazar J, Rojas-Quintero J, Cano C, et al. Neprilysin: a potential therapeutic target of arterial hypertension? Curr Cardiol Rev. 2020;16(1):25–35.
   PubMed Web of Science ®Google Scholar
• Campese VM, Tawadrous M, Bigazzi R, et al. Salt intake and plasma atrial natriuretic peptide and nitric oxide in hypertension. Hypertension. 1996;28(3):335–340.
   PubMed Web of Science ®Google Scholar
• Lieb W, Pencina MJ, Jacques PF, et al. Higher aldosterone and lower N-terminal proatrial natriuretic peptide as biomarkers of salt sensitivity in the community. Eur J Cardiovasc Prev Rehabil. 2011;18(4):664–673.
   PubMedGoogle Scholar
• John SW, Krege JH, Oliver PM, et al. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science. 1995;267(5198):679–681.
   PubMed Web of Science ®Google Scholar
• Pandey KN. Genetic ablation and guanylyl cyclase/natriuretic peptide receptor-A: impact on the pathophysiology of cardiovascular dysfunction. Int J Mol Sci. 2019;20(16):3946.
   Web of Science ®Google Scholar
• Oliver PM, Fox JE, Kim R, et al. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc Natl Acad Sci USA. 1997;94(26):14730–14735.
   PubMed Web of Science ®Google Scholar
• Campbell DJ. Long-term neprilysin inhibition – implications for ARNIs. Nat Rev Cardiol. 2017;14(3):171–186.
   PubMed Web of Science ®Google Scholar
• Campbell DJ. Neprilysin inhibitors and bradykinin. Front Med. 2018;5:257
   Web of Science ®Google Scholar
• Pajenda S, Mechtler K, Wagner L. Urinary neprilysin in the critically ill patient. BMC Nephrol. 2017;18(1):172.
   PubMedGoogle Scholar
• Elsner D, Muntze A, Kromer EP, et al. Effectiveness of endopeptidase inhibition (Candoxatril) in congestive heart failure. Am J Cardiol. 1992;70(4):494–498.
   PubMed Web of Science ®Google Scholar
• Bevan EG, Connell JM, Doyle J, et al. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens. 1992;10(7):607–613.
   PubMed Web of Science ®Google Scholar
• Favrat B, Burnier M, Nussberger J, et al. Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension. J Hypertens. 1995;13(7):797–804.
   PubMed Web of Science ®Google Scholar
• Kentsch M, Otter W, Drummer C, et al. Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure. Eur J Clin Pharmacol. 1996;51(3–4):269–272.
   PubMed Web of Science ®Google Scholar
• Brandenburg VM, Rocca HB, Marx N. [Sacubitril / Valsartan in patients with diabetes and heart failure]. Dtsch Med Wochenschr. 2016;141(22):1647–1649.
   PubMed Web of Science ®Google Scholar
• Heyse A, Manhaeghe L, Mahieu E, et al. Sacubitril/valsartan in heart failure and end-stage renal insufficiency. ESC Heart Fail. 2019;6(6):1331–1333.
   PubMed Web of Science ®Google Scholar
• Packer M, Claggett B, Lefkowitz MP, et al. Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2018;6(7):547–554.
   PubMed Web of Science ®Google Scholar
• Stork S. Renal effects of sacubitril/valsartan in patients with diabetes. Lancet Diabetes Endocrinol. 2018;6(7):519–521.
   PubMed Web of Science ®Google Scholar
• Polina I, Domondon M, Fox R, et al. Differential effects of low-dose sacubitril and/or valsartan on renal disease in salt-sensitive hypertension. Am J Physiol Renal Physiol. 2020;319(1):F63–F75.
   PubMed Web of Science ®Google Scholar
• Rieg T. A High-throughput method for measurement of glomerular filtration rate in conscious mice. J Vis Exp. 2013;(75):e50330.
   PubMed Web of Science ®Google Scholar
• Ilatovskaya DV, Levchenko V, Pavlov TS, et al. Salt-deficient diet exacerbates cystogenesis in ARPKD via epithelial sodium channel (ENaC). EBioMedicine. 2019;40:663–674.
   PubMed Web of Science ®Google Scholar
• Ilatovskaya DV, Staruschenko A. Single-channel analysis of TRPC channels in the podocytes of freshly isolated Glomeruli. Methods Mol Biol. 2013;998:355–369.
   PubMedGoogle Scholar
• Ilatovskaya DV, Levchenko V, Lowing A, et al. Podocyte injury in diabetic nephropathy: implications of angiotensin II-dependent activation of TRPC channels. Sci Rep. 2015;5:17637.
   PubMed Web of Science ®Google Scholar
• Farris AB, Ellis CL, Rogers TE, et al. Renal medullary and cortical correlates in fibrosis. PLoS One. 2016;11(8):e0161019.
   PubMed Web of Science ®Google Scholar
• Joe B. Dr Lewis Kitchener Dahl, the Dahl rats, and the “inconvenient truth” about the genetics of hypertension. Hypertension. 2015;65(5):963–969.
   PubMed Web of Science ®Google Scholar
• Oh YS, Appel LJ, Galis ZS, et al. National Heart, Lung, and Blood Institute Working Group report on salt in human health and sickness: building on the current scientific evidence. Hypertension. 2016;68(2):281–288.
   PubMed Web of Science ®Google Scholar
• Flister MJ, Tsaih SW, O’Meara CC, et al. Identifying multiple causative genes at a single GWAS locus. Genome Res. 2013;23(12):1996–2002.
   PubMed Web of Science ®Google Scholar
• Gupta DK, Daniels LB, Cheng S, et al. Differences in natriuretic peptide levels by race/ethnicity (from the multi-ethnic study of atherosclerosis). Am J Cardiol. 2017;120(6):1008–1015.
   PubMed Web of Science ®Google Scholar
• Beyer AM, Raffai G, Weinberg B, et al. Dahl salt-sensitive rats are protected against vascular defects related to diet-induced obesity. Hypertension. 2012;60(2):404–410.
   PubMed Web of Science ®Google Scholar
• Conceicao G, Heinonen I, Lourenco AP, et al. Animal models of heart failure with preserved ejection fraction. Neth Heart J. 2016;24(4):275–286.
   PubMed Web of Science ®Google Scholar
• Zucker IH, Xiao L, Haack KK. The central renin-angiotensin system and sympathetic nerve activity in chronic heart failure. Clin Sci. 2014;126(10):695–706.
   Web of Science ®Google Scholar
• Jia G, Aroor AR, Hill MA, et al. Role of renin-angiotensin-aldosterone system activation in promoting cardiovascular fibrosis and stiffness. Hypertension. 2018;72(3):537–548.
   PubMed Web of Science ®Google Scholar
• Suematsu Y, Jing W, Nunes A, et al. LCZ696 (Sacubitril/Valsartan), an angiotensin-receptor neprilysin inhibitor, attenuates cardiac hypertrophy, fibrosis, and vasculopathy in a rat model of chronic kidney disease. J Card Fail. 2018;24(4):266–275.
   PubMed Web of Science ®Google Scholar
• McMurray JJ. Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances. Eur J Heart Fail. 2015;17(3):242–247.
   PubMed Web of Science ®Google Scholar
• Kahn JC, Patey M, Dubois-Rande JL, et al. Effect of sinorphan on plasma atrial natriuretic factor in congestive heart failure. Lancet. 1990;335(8681):118–119.
   PubMed Web of Science ®Google Scholar
• Guo DF, Chenier I, Lavoie JL, et al. Development of hypertension and kidney hypertrophy in transgenic mice overexpressing ARAP1 gene in the kidney. Hypertension. 2006;48(3):453–459.
   PubMed Web of Science ®Google Scholar
• Habib SL. Kidney atrophy vs hypertrophy in diabetes: which cells are involved? Cell Cycle. 2018;17(14):1683–1687.
   PubMed Web of Science ®Google Scholar
• Bidani AK, Polichnowski AJ, Loutzenhiser R, et al. Renal microvascular dysfunction, hypertension and CKD progression. Curr Opin Nephrol Hypertens. 2013;22(1):1–9.
   PubMed Web of Science ®Google Scholar
• Mohany M, Alanazi AZ, Alqahtani F, et al. LCZ696 mitigates diabetic-induced nephropathy through inhibiting oxidative stress, NF-kappaB mediated inflammation and glomerulosclerosis in rats. PeerJ. 2020;8:e9196.
   PubMed Web of Science ®Google Scholar
• Chen X, Jin C, Xie L, et al. LCZ696 and preservation of renal function in heart failure: a meta-analysis of 6 randomized trials. Rev Cardiovasc Med. 2020;21(1):113–118.
   PubMed Web of Science ®Google Scholar
• Campbell DJ, Anastasopoulos F, Duncan AM, et al. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats. J Pharmacol Exp Ther. 1998;287(2):567–577.
   PubMed Web of Science ®Google Scholar
• Richards AM, Wittert GA, Espiner EA, et al. Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers. Circ Res. 1992;71(6):1501–1507.
   PubMed Web of Science ®Google Scholar
• Ferro CJ, Spratt JC, Haynes WG, et al. Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation. 1998;97(23):2323–2330.
   PubMed Web of Science ®Google Scholar
• Qin L, Du Y, Ding H, et al. Bradykinin 1 receptor blockade subdues systemic autoimmunity, renal inflammation, and blood pressure in murine lupus nephritis. Arthritis Res Ther. 2019;21(1):12.
   PubMedGoogle Scholar